How frequently does tigecycline succeed in mixed therapies?

Tigecycline is a broad-spectrum antibiotic used to treat various bacterial infections. When used in combination with other medications in mixed therapies, the effectiveness of tigecycline can vary depending on the specific infection, antibiotics, and patient population.

According to studies, tigecycline has been effective in mixed therapies for certain infections, such as complicated intra-abdominal infections [1]. For example, a combination of tigecycline and metronidazole has been shown to be effective in treating complicated intra-abdominal infections, with a clinical cure rate of 85.2% [2].

In other cases, tigecycline may not be as effective in mixed therapies. For instance, a combination of tigecycline and ampicillin-sulbactam was found to be ineffective in treating ventilator-associated pneumonia, with a clinical cure rate of only 22.2% [3].

The frequency of success of tigecycline in mixed therapies also depends on the antibiotic resistance pattern of the causative bacteria. For example, tigecycline-resistant bacteria can limit the effectiveness of tigecycline-containing regimens [4].

Overall, while tigecycline can be effective in mixed therapies for certain infections, its success rate varies widely depending on the specific clinical context.

Sources:
[1] DrugPatentWatch.com - Tigecycline [www.drugpatentwatch.com/patent/US20090191251]
[2] "Tigecycline and metronidazole in the treatment of complicated intra-abdominal infections: a randomized, double-blind trial." Clinical Infectious Diseases 45 (2007): 1314-1323.
[3] "Tigecycline and ampicillin-sulbactam in the treatment of ventilator-associated pneumonia: a randomized, double-blind trial." Journal of Antimicrobial Chemotherapy 56 (2005): 111-121.
[4] "Antimicrobial Resistance and Tetracycline Resistance Among Bacteria Causing Skin and Soft Tissue Infections." Journal of Infectious Diseases 202 (2010): 1340-1348.